Phenominer Database Results (580 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
WKY systolic blood pressure controlled sodium content diet (0.4 %) (for 63 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. arterial blood pressure trait male 91.0 days 4 serial mean 131.7 mmHg 2.25 4.5 tail cuff photoplethysmography 0 UR1000; Ueda average of 3 consistent readings 12584 268
WKY body weight controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. body mass female 360.0 days 4 200.8 g 3.45 6.9 body weighing method 0 12589 268
WKY decrease in blood ethanol level to body weight ratio per unit time ethanol (20 %) (between 0.5 and 3.5 hours) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. ethanol metabolism trait male 80.0 days-90.0 days 315.0 mg/kg/h 6.0 enzymatic microassay 0.0 96820 1238
WKY blood ethanol clearance rate ethanol (20 %) (between 0.5 and 3.5 hours) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. ethanol metabolism trait female 80.0 days-90.0 days 41.3 mg/dl/h 3.1 enzymatic microassay 0.0 97044 1238
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 12 323.0 g 5.0 17.32 body weighing method 0.0 PA IV 50mg/kg 100395 2479
WKY serum triglyceride level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 12 73.0 mg/dl 5.0 17.32 serum triglyceride analysis 0.0 PA IV 50mg/kg 100413 2479
WKY afferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 9 5.6 g/dl 0.1 0.3 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg ca 100570 2479
WKY efferent arteriolar plasma protein concentration 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 9 7.5 g/dl 0.2 0.6 plasma total protein analysis renal efferent arteriole 0.0 ce 100572 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 18.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg ce 100580 2479
WKY efferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 31.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 pie 100584 2479
WKY glomerular capillary ultrafiltration coefficient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.07 nl/(s x mmHg) 0.01 0.04 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 kf 100587 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.04 nl/(s x mmHg) 0.0 0.01 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg kf 100590 2479
WKY right kidney wet weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 15 1.37 g 0.04 0.14 post excision weight measurement 0.0 lad occlusion 196 days 100372 2460
WKY heart left ventricle infarction size to total heart left ventricle size ratio left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle integrity trait male 238.0 days-252.0 days 30 35.8 % 5.4 29.58 ex vivo microscopy with digital image analysis 0.0 lad occlusion 196 days 100264 2460
WKY heart left ventricle infarction size to total heart left ventricle size ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle integrity trait male 266.0 days-280.0 days 32 30.9 % 8.1 45.82 ex vivo microscopy with digital image analysis 0.0 lad occlusion 210 days 100266 2460
WKY body weight left anterior descending coronary artery occlusion then furosemide Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 42.0 days-56.0 days 20 225.0 g 3.0 13.42 body weighing method 0.0 lad occlusion days 100268 2460
WKY body weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 238.0 days-252.0 days 20 583.0 g 56.0 250.44 body weighing method 0.0 lad occlusion 196 days 100271 2460
WKY heart weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 238.0 days-252.0 days 12 1.19 g 0.04 0.13 post excision weight measurement 0.0 lad occlusion sham 196 days 100276 2460
WKY heart left ventricle weight to tibia length ratio sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 5 0.19 g/cm 0.01 0.01 post excision weight measurement 0.0 lad occlusion sham 210 days lv/tl 100294 2460
WKY lung wet weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. lung mass male 238.0 days-252.0 days 30 2.13 g 0.13 0.71 post excision weight measurement 0.0 lad occlusion 196 days 100299 2460
WKY timed urine volume streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 53.91 ml/d 7.67 24.25 urine volume measurement method 0.0 99124 2219
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) (for 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 118.0 mmHg 4.0 8.94 tail cuff plethysmography 0.0 PA IV 50mg/kg 70 days 100593 2479
WKY systolic blood pressure 0.9% sodium chloride solution (50 mg/kg) (for 0.5 hours) then 0.9% sodium chloride solution Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 131.0 mmHg 4.0 8.94 tail cuff plethysmography 0.0 PA IV 50mg/kg 100595 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 1.24 ml/min 0.07 0.16 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100598 2479
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 16 308.0 mg/dl 15.0 60.0 machine read blood glucose test strip 0.0 unx 168 days 99973 2378
WKY hematocrit unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity male  days 17 45.6 % 0.3 1.24 hematocrit analysis 0.0 unx 168 days 99977 2378
WKY hematocrit unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity male  days 16 45.8 % 0.5 2.0 hematocrit analysis 0.0 unx 168 days 99978 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 11 2.28 ml/min/100g 0.07 0.23 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99990 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 16 3.15 ml/min/100g 0.13 0.52 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99993 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 11 6.3 mmHg/ml/min 0.4 1.33 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99995 2378
WKY right kidney wet weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 15 1.35 g 0.04 0.17 post excision weight measurement 0.0 lad occlusion 196 days 100373 2460
WKY timed urine volume left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 11.4 ml/d 2.4 6.35 urine volume measurement method 0.0 lad occlusion 196 days 100375 2460
WKY timed urine volume left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 10.6 ml/d 2.2 5.82 urine volume measurement method 0.0 lad occlusion 196 days 100376 2460
WKY kidney angiotensin I converting enzyme activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 0.35 nmol/min/mg 0.06 0.13 high-performance liquid chromatography 0.0 99085 2218
WKY kidney angiotensin I converting enzyme activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 0.39 nmol/min/mg 0.08 0.2 high-performance liquid chromatography 0.0 99088 2218
WKY urine potassium level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. urine potassium amount male 112.0 days 7 112.58 mmol/l 26.7 70.64 inductively coupled plasma-atomic emission spectrometry 0.0 99096 2218
WKY urine sodium level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. urine sodium amount male 112.0 days 7 55.41 mmol/l 18.4 48.68 inductively coupled plasma-atomic emission spectrometry 0.0 99094 2218
WKY body weight vehicle control condition (1 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 450.39 g 9.36 29.6 body weighing method 0.0 99107 2219
WKY blood glucose level streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 537.12 mg/dl 28.98 91.64 radioimmunoassay 0.0 99105 2219
WKY single kidney wet weight to body weight ratio streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 4.72 g/kg 0.31 0.98 post excision weight measurement 0.0 99118 2219
WKY timed urine volume streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 133.86 ml/d 16.58 52.43 urine volume measurement method 0.0 99121 2219
WKY plasma total cholesterol level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood cholesterol amount male  days 7 61.39 mg/dl 4.25 11.24 enzymatic cholesterol assay 0.0 98902 2178
WKY plasma total cholesterol level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood cholesterol amount male  days 7 66.02 mg/dl 3.86 10.22 enzymatic cholesterol assay 0.0 98903 2178
WKY plasma low density lipoprotein cholesterol level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood LDL cholesterol amount male  days 7 10.04 mg/dl 1.16 3.06 enzymatic cholesterol assay 0.0 98910 2178
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 11 249.0 g 11.0 36.48 body weighing method 0.0 PA IV 50mg/kg 15 days 100392 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 7 245.0 g 9.0 23.81 body weighing method 0.0 PA IV 50mg/kg 15 days 100428 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 9 297.0 g 4.0 12.0 body weighing method 0.0 PA IV 50mg/kg 100431 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 8 305.0 g 6.0 16.97 body weighing method 0.0 PA IV 50mg/kg 100432 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 7 39.0 % 1.0 2.65 hematocrit analysis 0.0 PA IV 50mg/kg 23 days 100437 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 9 395.0 g 7.0 21.0 body weighing method 0.0 PA IV 50mg/kg 490 days 100435 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 8 43.0 % 1.0 2.83 hematocrit analysis 0.0 PA IV 50mg/kg 100441 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 95.0 mmHg 9.0 20.12 tail cuff plethysmography 0.0 PA IV 50mg/kg 15 days 100447 2479
WKY systolic blood pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 9 108.0 mmHg 3.0 9.0 tail cuff plethysmography 0.0 100451 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 1.25 ml/min 0.09 0.25 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100459 2479
WKY plasma corticosterone level controlled calorie content diet (30 % of calories) (for 14 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood corticosterone amount female  days 6 409.0 ng/ml 28.0 68.59 radioimmunoassay 0.0 99071 2218
WKY body weight 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 10 241.0 g 5.0 15.81 body weighing method 0.0 100391 2479
WKY serum albumin level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 12 3.8 g/dl 0.1 0.35 radial immunodiffusion assay 0.0 PA IV 50mg/kg 100419 2479
WKY single nephron glomerular filtration rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 44.4 nl/min 4.0 12.0 inulin analysis by liquid phase colorimetry 0.0 sngfr 100517 2479
WKY mean proximal tubular hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 14.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 pt 100537 2479
WKY glomerular transcapillary hydraulic pressure gradient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 33.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 dp 100549 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 6 1.6 x 10E10 dyne x s/cm5 0.22 0.54 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days ra 100553 2479
WKY body weight unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 8 215.0 g 10.0 28.28 body weighing method 0.0 unx 28 days 99936 2378
WKY blood glucose level unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 7 74.0 mg/dl 2.0 5.29 machine read blood glucose test strip 0.0 unx 28 days 99940 2378
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 8 357.0 mg/dl 11.0 31.11 machine read blood glucose test strip 0.0 unx 28 days 99943 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 7 0.49 ml/min/100g 0.03 0.08 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99945 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 8 3.09 ml/min/100g 0.18 0.51 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99951 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.26 null 0.01 0.04 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99956 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.23 null 0.14 0.4 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99958 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.23 null 0.12 0.34 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99957 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 6 8.8 mmHg/ml/min 0.5 1.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99964 2378
WKY heart left ventricle end-systolic diameter sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 266.0 days-280.0 days 5 3.8 mm 0.3 0.67 echocardiography 0.0 lad occlusion sham 210 days 100309 2460
WKY heart left ventricle fractional shortening left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 16 16.8 % 1.6 6.4 echocardiography 0.0 lad occlusion 210 days 100304 2460
WKY heart rate left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart pumping trait male 266.0 days-280.0 days 16 362.0 beats/min 31.0 124.0 echocardiography 0.0 lad occlusion 210 days 100313 2460
WKY systolic blood pressure sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 5 10 min mean continuous mean 97.8 mmHg 6.3 14.09 vascular transducer tipped catheter 0.0 lad occlusion sham 210 days 100315 2460
WKY diastolic blood pressure sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 5 10 min mean continuous mean 63.3 mmHg 6.9 15.43 vascular transducer tipped catheter 0.0 lad occlusion sham 210 days 100318 2460
WKY serum sodium level sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood sodium amount male 266.0 days-280.0 days 5 157.7 mmol/l 6.4 14.31 automated serum sodium test 0.0 lad occlusion sham 210 days 100330 2460
WKY left ventricular end-diastolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 16 10 min mean continuous mean 9.36 mmHg 1.62 6.48 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100325 2460
WKY maximum rate of positive change in left ventricular blood pressure sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 5 10 min mean continuous mean 4225.0 mmHg/s 525.0 1173.94 vascular transducer tipped catheter 0.0 lad occlusion sham 210 days 100327 2460
WKY heart ventricle septal wall thickness left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle wall thickness male 238.0 days-252.0 days 30 0.1 cm 0.0 0.02 echocardiography 0.0 lad occlusion 196 days 100338 2460
WKY heart left ventricle end-systolic diameter left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 238.0 days-252.0 days 20 9.0 mm 0.2 0.89 echocardiography 0.0 lad occlusion 196 days 100343 2460
WKY heart left ventricle end-systolic diameter left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 238.0 days-252.0 days 30 8.9 mm 0.2 1.1 echocardiography 0.0 lad occlusion 196 days 100344 2460
WKY ejection fraction sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 238.0 days-252.0 days 12 75.8 % 3.9 13.51 echocardiography 0.0 lad occlusion sham 196 days 100351 2460
WKY ejection fraction left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 238.0 days-252.0 days 20 35.5 % 2.0 8.94 echocardiography 0.0 lad occlusion 196 days 100352 2460
WKY plasma creatinine level left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.52 mg/dl 0.04 0.1 plasma creatinine analysis 0.0 lad occlusion 196 days 100365 2460
WKY afferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 1.04 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg ra 100556 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 0.5 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg re 100561 2479
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 6 2.43 x 10E10 dyne x s/cm5 0.28 0.69 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days rt 100563 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 3.95 ml/min 0.7 1.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100465 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 4.65 ml/min 0.55 1.56 p-aminohippurate analysis by liquid phase colorimetry 0.0 100466 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 5.45 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100471 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.09 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100474 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.32 null 0.03 0.09 p-aminohippurate analysis by liquid phase colorimetry 0.0 100478 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 7 149.0 mmol/l 3.0 7.94 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100482 2479
WKY plasma sodium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 8 150.0 mmol/l 2.0 5.66 automated plasma analysis 0.0 100484 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 5 138.0 mmol/l 2.0 4.47 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100483 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 7 5.9 mmol/l 0.3 0.79 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100491 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 7 0.2 mEq/d 0.03 0.08 urine potassium analysis 0.0 PA IV 50mg/kg 15 days 100509 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 9 0.5 mEq/d 0.04 0.13 urine potassium analysis 0.0 PA IV 50mg/kg 100512 2479
WKY urine total protein excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 11 8.0 mg/d 1.0 3.32 metabolic cage urine volume measurement method 0.0 100400 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 12 10.0 mg/d 1.0 3.46 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 100402 2479
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction diclofenac (10 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 11.8 gx10 0.45 1.19 Randall-Selitto test 60 min 0.1% methylcellulose per os 108347 3101
WKY systolic blood pressure diclofenac (10 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 123.7 mmHg 1.06 2.8 tail cuff plethysmography 60 min IP 108359 3101
WKY body weight unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 17 256.0 g 5.0 20.62 body weighing method 0.0 unx 150 days 107446 2378
WKY kidney glomerular tuft surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 17 11.8 x 10E3 um2 2.9 11.96 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107512 2378
WKY kidney glomerular surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 17 17.0 x 10E3 um2 4.1 16.9 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107462 2378
WKY kidney glomerular surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 16 15.8 x 10E3 um2 4.0 16.0 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107463 2378
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 21.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 109966 2479
WKY systolic blood pressure control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. arterial blood pressure trait male 420.0 days 4 136.0 mmHg 2.5 5.0 tail cuff plethysmography 0.0 109530 3147
WKY serum creatinine level control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. blood creatinine amount male 280.0 days 4 0.33 mg/dl 0.03 0.06 serum creatinine analysis 0.0 109546 3147
WKY serum creatinine level control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. blood creatinine amount male 420.0 days 4 0.32 mg/dl 0.04 0.07 serum creatinine analysis 0.0 109548 3147
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 4.36 ml/min 0.36 0.8 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100602 2479
WKY heart left ventricle weight to body weight ratio control condition (for 0 hours) Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. heart left ventricle mass male 84.0 days 5 2.29 mg/g 0.03 0.07 post excision weight measurement 0.0 103482 2826
WKY diastolic blood pressure control condition Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46 arterial blood pressure trait male 175.0 days 24 continuous mean 102.1 mmHg 2.47 12.1 vascular indwelling catheter method aorta 11902 206
WKY ethanol drink intake rate to body weight ratio controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. drinking behavior trait male 80.0 days-90.0 days 5 0.56 g/d/kg 0.08 0.19 ex vivo volume measurement method 0.0 69898 1238
WKY ethanol drink intake rate to body weight ratio controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. drinking behavior trait female 80.0 days-90.0 days 11 2.54 g/d/kg 2.86 9.5 ex vivo volume measurement method 0.0 69899 1238
WKY decrease in blood ethanol level to body weight ratio per unit time ethanol (20 %) (between 0.5 and 3.5 hours) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. ethanol metabolism trait female 80.0 days-90.0 days 379.0 mg/kg/h 8.0 enzymatic microassay 0.0 97040 1238
WKY serum triglyceride level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 11 55.0 mg/dl 6.0 19.9 serum triglyceride analysis 0.0 100412 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 12 72.0 mg/dl 9.0 31.18 serum triglyceride analysis 0.0 PA IV 50mg/kg 100414 2479
WKY afferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 6 4.7 g/dl 0.2 0.49 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg 23 days rt 100568 2479
WKY efferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 29.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 pie 100582 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 14.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pie 100583 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 6 0.02 nl/(s x mmHg) 0.0 0.01 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 15 days kf 100588 2479
WKY systolic blood pressure controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. arterial blood pressure trait male 112.0 days 6 undefined 125.0 mmHg 2.0 4.9 tail cuff plethysmography 0.0 101684 2218
WKY plasma angiotensin II level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood angiotensin II amount male 112.0 days 6 41.3 pg/ml 11.5 28.17 immunoassay 0.0 101689 2218
WKY systolic blood pressure control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. arterial blood pressure trait male 280.0 days 9 undefined 130.0 mmHg 2.33 7.0 tail cuff plethysmography 0.0 100232 2459
WKY urine total protein excretion rate control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. total urine protein amount male 280.0 days 9 20.0 mg/d 1.33 4.0 urine total protein analysis 0.0 100239 2459
WKY kidney glomerulus volume control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. kidney glomerulus morphology trait male 280.0 days 9 0.7 x 10E6 um3 0.02 0.07 ex vivo light microscopy with digital image analysis 0.0 100252 2459
WKY kidney sclerotic glomeruli count to total glomeruli count ratio control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. kidney glomerulus integrity trait male 280.0 days 9 4.0 % 1.33 4.0 ex vivo light microscopy with digital image analysis 0.0 100256 2459
WKY body weight sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 266.0 days-280.0 days 5 562.0 g 22.0 49.19 body weighing method 0.0 lad occlusion sham 210 days 100273 2460
WKY body weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 238.0 days-252.0 days 30 617.0 g 52.0 284.82 body weighing method 0.0 lad occlusion 196 days 100272 2460
WKY tibia length sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. tibia length male 266.0 days-280.0 days 5 4.3 cm 0.12 0.27 post excision length measurement 0.0 lad occlusion sham 210 days 100285 2460
WKY heart left ventricle weight sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 5 0.84 g 0.02 0.05 post excision weight measurement 0.0 lad occlusion sham 210 days 100291 2460
WKY heart left ventricle weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 16 1.04 g 0.13 0.51 post excision weight measurement 0.0 lad occlusion 210 days 100292 2460
WKY ejection fraction left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 266.0 days-280.0 days 16 38.5 % 3.2 12.8 echocardiography 0.0 lad occlusion 210 days 100301 2460
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 1.22 ml/min 0.03 0.07 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100596 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 127.0 mmHg 5.0 11.18 tail cuff plethysmography 0.0 PA IV 50mg/kg 100594 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 4.37 ml/min 0.24 0.54 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100603 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.29 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100606 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.06 nl/(s x mmHg) 0.02 0.04 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg kf 100616 2479
WKY hematocrit unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity male  days 17 44.8 % 0.6 2.47 hematocrit analysis 0.0 unx 168 days 99976 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 17 0.69 ml/min/100g 0.03 0.13 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99982 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 11 11.66 ml/d 1.01 3.34 metabolic cage urine volume measurement method 0.0 unx 168 days 100000 2378
WKY blood urea nitrogen level control condition Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. blood urea nitrogen amount male 245.0 days 7 19.5 mg/dl 0.98 2.6 blood urea nitrogen analysis 0.0 99857 2338
WKY kidney fibrotic lesion area to total kidney area ratio sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney integrity trait male 238.0 days-252.0 days 11 0.91 % 0.03 0.1 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion sham 196 days 100383 2460
WKY plasma sodium level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood sodium amount male 112.0 days 7 139.41 mmol/l 4.17 11.03 inductively coupled plasma-atomic emission spectrometry 0.0 99089 2218
WKY urine potassium level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. urine potassium amount male 112.0 days 7 122.72 mmol/l 30.2 79.9 inductively coupled plasma-atomic emission spectrometry 0.0 99095 2218
WKY blood glucose level vehicle control condition (1 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 160.56 mg/dl 8.64 27.32 radioimmunoassay 0.0 99101 2219
WKY single kidney wet weight to body weight ratio vehicle control condition (1 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 3.41 g/kg 0.34 1.08 post excision weight measurement 0.0 99113 2219
WKY body weight streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 287.24 g 20.18 63.81 body weighing method 0.0 99111 2219
WKY single kidney wet weight to body weight ratio streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 4.46 g/kg 0.42 1.33 post excision weight measurement 0.0 99116 2219
WKY timed urine volume streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 58.33 ml/d 8.45 26.72 urine volume measurement method 0.0 99123 2219
WKY liver triglyceride level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. liver triglyceride amount male  days 7 11.42 mg/g 1.08 2.86 enzymatic triglyceride assay 0.0 98898 2178
WKY plasma triglyceride level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood triglyceride amount male  days 7 0.48 mmol/l 0.02 0.05 enzymatic triglyceride assay 0.0 98918 2178
WKY heart angiotensin I converting enzyme 2 activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 0.02 nmol/min/mg 0.01 0.02 high-performance liquid chromatography 0.0 99080 2218
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 8 418.0 g 15.0 42.43 body weighing method 0.0 PA IV 50mg/kg 490 days 100434 2479
WKY hematocrit 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 8 45.0 % 1.0 2.83 hematocrit analysis 0.0 100439 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 1.43 ml/min 0.09 0.27 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100462 2479
WKY serum albumin level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 11 1.3 g/dl 0.1 0.33 radial immunodiffusion assay 0.0 PA IV 50mg/kg 23 days 100416 2479
WKY plasma renin activity level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 10 10.7 ng/ml/h 1.7 5.38 radioimmunoassay 0.0 100421 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 6 17.0 nl/min 2.0 4.9 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days sngfr 100518 2479
WKY single nephron glomerular filtration rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 52.0 nl/min 3.0 8.49 inulin analysis by liquid phase colorimetry 0.0 sngfr 100519 2479
WKY single nephron filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 snff 100522 2479
WKY single nephron filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.26 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100526 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 169.0 nl/min 14.0 42.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg afferent arteriolar plasma flow rate 100530 2479
WKY glomerular capillary hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 49.0 mmHg 1.0 3.0 inulin analysis by liquid phase colorimetry 0.0 pgc 100532 2479
WKY mean proximal tubular hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 14.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 pt 100539 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 15.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 100538 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 6 21.0 x 10E10 dyne x s/cm5 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pe 100543 2479
WKY afferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 1.68 x 10E10 dyne x s/cm5 0.14 0.4 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 ra 100554 2479
WKY body weight unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 8 236.0 g 7.0 19.8 body weighing method 0.0 unx 28 days 99937 2378
WKY body weight unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 6 229.0 g 6.0 14.7 body weighing method 0.0 unx 28 days 99939 2378
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 8 352.0 mg/dl 17.0 48.08 machine read blood glucose test strip 0.0 unx 28 days 99942 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.79 ml/min/100g 0.03 0.08 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99946 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 8 9.0 mmHg/ml/min 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99961 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 7 12.38 ml/d 2.02 5.33 metabolic cage urine volume measurement method 0.0 unx 28 days 99965 2378
WKY heart left ventricle fractional shortening left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 32 18.0 % 1.5 8.49 echocardiography 0.0 lad occlusion 210 days 100305 2460
WKY heart left ventricle end-systolic diameter left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 266.0 days-280.0 days 16 9.1 mm 0.4 1.6 echocardiography 0.0 lad occlusion 210 days 100310 2460
WKY systolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 16 10 min mean continuous mean 79.5 mmHg 5.1 20.4 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100316 2460
WKY maximum rate of positive change in left ventricular blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 32 10 min mean continuous mean 2882.0 mmHg/s 208.0 1176.63 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100329 2460
WKY serum sodium level left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood sodium amount male 266.0 days-280.0 days 32 155.1 mmol/l 1.1 6.22 automated serum sodium test 0.0 lad occlusion 210 days 100332 2460
WKY heart left ventricle end-diastolic diameter left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 30 10.6 mm 0.1 0.55 echocardiography 0.0 lad occlusion 196 days 100341 2460
WKY heart posterior wall thickness left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle posterior wall thickness male 238.0 days-252.0 days 30 0.18 cm 0.0 0.02 echocardiography 0.0 lad occlusion 196 days 100347 2460
WKY E/A wave ratio left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood flow trait male 238.0 days-252.0 days 20 1.61 null 0.21 0.94 echocardiography 0.0 lad occlusion 196 days 100355 2460
WKY E/A wave ratio left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood flow trait male 238.0 days-252.0 days 30 1.85 null 0.14 0.77 echocardiography 0.0 lad occlusion 196 days 100356 2460
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 0.82 x 10E10 dyne x s/cm5 0.08 0.23 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 re 100559 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 1.54 x 10E10 dyne x s/cm5 0.12 0.36 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg re 100560 2479
WKY total arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 2.49 x 10E10 dyne x s/cm5 0.21 0.59 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 rt 100564 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100477 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.27 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100479 2479
WKY plasma sodium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 9 152.0 mmol/l 2.0 6.0 automated plasma analysis 0.0 100481 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100480 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 9 4.4 mmol/l 0.1 0.3 automated plasma analysis 0.0 PA IV 50mg/kg 100494 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 8 5.0 mmol/l 0.4 1.13 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100497 2479
WKY plasma potassium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 9 4.2 mmol/l 0.2 0.6 automated plasma analysis 0.0 100496 2479
WKY urine sodium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 9 0.53 mEq/d 0.07 0.22 urine sodium analysis 0.0 100499 2479
WKY urine sodium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 9 0.59 mEq/d 0.16 0.48 urine sodium analysis 0.0 100505 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 9 0.33 mEq/d 0.04 0.13 urine sodium analysis 0.0 PA IV 50mg/kg 100503 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 8 0.73 mEq/d 0.2 0.57 urine sodium analysis 0.0 PA IV 50mg/kg 490 days 100506 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 8 0.49 mEq/d 0.04 0.12 urine potassium analysis 0.0 PA IV 50mg/kg 100513 2479
WKY serum total cholesterol level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 11 240.0 mg/dl 15.0 49.75 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 19 days 100404 2479
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 11.3 gx10 0.41 1.08 Randall-Selitto test 108345 3101
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction diclofenac (20 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 11.4 gx10 0.34 0.89 Randall-Selitto test 60 min 0.1% methylcellulose per os 108351 3101
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction diclofenac (40 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 12.8 gx10 0.4 1.06 Randall-Selitto test 60 min 0.1% methylcellulose per os 108355 3101
WKY body weight unilateral nephrectomy (for 150 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 11 408.0 g 10.0 33.17 body weighing method 0.0 unx 150 days 107445 2378
WKY left kidney wet weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass male  days 17 9.9 mg/g 0.7 2.89 post excision weight measurement 0.0 unx 150 days 107456 2378
WKY left kidney wet weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass male  days 16 8.1 mg/g 0.2 0.8 post excision weight measurement 0.0 unx 150 days 107458 2378
WKY kidney glomerular surface area unilateral nephrectomy (for 150 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 11 12.6 x 10E3 um2 3.8 12.6 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107460 2378
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 22.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pt 109968 2479
WKY urine total protein excretion rate control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. total urine protein amount male 420.0 days 4 16.0 mg/d 3.0 6.0 urine total protein analysis 0.0 109539 3147
WKY urine total protein excretion rate control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. total urine protein amount male 350.0 days 4 19.0 mg/d 2.0 4.0 urine total protein analysis 0.0 109538 3147
WKY mean arterial blood pressure control condition Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46 arterial blood pressure trait male 140.0 days 28 continuous mean 126.0 mmHg 1.38 7.3 tail cuff plethysmography 0 animals were prewarmed to 34 degrees C for 20 min before BP 65084 206
WKY systolic blood pressure control condition Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46 arterial blood pressure trait male 175.0 days 24 continuous mean 167.3 mmHg 2.37 11.6 vascular indwelling catheter method aorta 11901 206
WKY heart wet weight controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. heart mass male 360.0 days 4 0.78 g 0.03 0.06 post excision weight measurement 0 12592 268
WKY heart weight to body weight ratio controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. heart mass female 360.0 days 4 2.8 g/kg 0.1 0.2 post excision weight measurement 0 12596 268
WKY blood ethanol clearance rate ethanol (20 %) (between 0.5 and 3.5 hours) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. ethanol metabolism trait male 80.0 days-90.0 days 33.6 mg/dl/h 1.1 enzymatic microassay 0.0 97043 1238
WKY serum total cholesterol level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 12 88.0 mg/dl 5.0 17.32 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 100407 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 10 240.0 mg/dl 19.0 60.08 serum triglyceride analysis 0.0 PA IV 50mg/kg 19 days 100411 2479
WKY afferent arteriolar plasma protein concentration 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 9 5.4 g/dl 0.1 0.3 plasma total protein analysis renal afferent arteriole 0.0 ca 100567 2479
WKY afferent arteriolar plasma protein concentration 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 5.6 g/dl 0.1 0.28 plasma total protein analysis renal afferent arteriole 0.0 ca 100569 2479
WKY efferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 9 8.1 g/dl 0.2 0.6 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg ce 100575 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 12.0 mmHg 0.3 0.73 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days pia 100578 2479
WKY efferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 7.5 g/dl 0.3 0.85 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg ce 100576 2479
WKY efferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 29.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pie 100586 2479
WKY glomerular capillary ultrafiltration coefficient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.11 nl/(s x mmHg) 0.03 0.07 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg kf 100591 2479
WKY mean arterial blood pressure controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. arterial blood pressure trait male 112.0 days 5 undefined 66.0 mmHg 2.0 4.47 tail cuff plethysmography 0.0 101685 2218
WKY plasma angiotensin II level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood angiotensin II amount male 112.0 days 7 73.8 pg/ml 12.7 33.6 immunoassay 0.0 101690 2218
WKY plasma aldosterone level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood aldosterone amount male 112.0 days 6 1130.0 pg/ml 240.0 587.88 radioimmunoassay 0.0 101692 2218
WKY serum creatinine level control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. blood creatinine amount male 280.0 days 9 0.53 mg/dl 0.03 0.1 serum creatinine analysis 0.0 100246 2459
WKY heart left ventricle infarction size to total heart left ventricle size ratio left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle integrity trait male 238.0 days-252.0 days 20 35.2 % 4.5 20.12 ex vivo microscopy with digital image analysis 0.0 lad occlusion 196 days 100263 2460
WKY kidney sclerotic glomerular volume to total kidney glomerular volume ratio control condition (for 280 days) Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22. kidney glomerulus integrity trait male 280.0 days 9 0.3 % 0.13 0.4 ex vivo light microscopy with digital image analysis 0.0 100260 2459
WKY heart weight to tibia length ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 16 0.4 g/cm 0.1 0.4 post excision weight measurement 0.0 lad occlusion 210 days 100283 2460
WKY heart weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 32 1.44 g 0.37 2.09 post excision weight measurement 0.0 lad occlusion 210 days 100281 2460
WKY tibia length left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. tibia length male 266.0 days-280.0 days 16 4.3 cm 0.09 0.36 post excision length measurement 0.0 lad occlusion 210 days 100286 2460
WKY lung wet weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. lung mass male 238.0 days-252.0 days 20 2.24 g 0.19 0.85 post excision weight measurement 0.0 lad occlusion 196 days 100298 2460
WKY heart angiotensin I converting enzyme 2 activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 0.02 nmol/min/mg 0.01 0.02 high-performance liquid chromatography 0.0 99077 2218
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 3.9 ml/min 0.2 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100600 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 4.6 ml/min 0.1 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100601 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.32 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100605 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 57.0 nl/min 8.0 17.89 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg sngfr 100611 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) (for 0.5 hours) then saralasin (0.3 mg/kg/hr) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 314.0 nl/min 34.0 76.03 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg qa 100613 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) (between 56 and 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 5 51.0 mmHg 3.0 6.71 micropuncture fluid collection 0.0 PA IV 50mg/kg pgc 100615 2479
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 16 317.0 mg/dl 19.0 76.0 machine read blood glucose test strip 0.0 unx 168 days 99974 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 11 0.52 ml/min/100g 0.01 0.04 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99980 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 11 0.23 null 0.01 0.03 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99985 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 17 16.7 mmHg/ml/min 1.4 5.77 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99996 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 17 41.47 ml/d 4.46 18.41 metabolic cage urine volume measurement method 0.0 unx 168 days 100002 2378
WKY plasma creatinine level sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.41 mg/dl 0.03 0.07 plasma creatinine analysis 0.0 lad occlusion sham 196 days 100377 2460
WKY artery tunica media width to artery inner diameter ratio sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney blood vessel morphology trait male 238.0 days-252.0 days 11 1.89 null 0.12 0.4 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion sham 196 days 100386 2460
WKY kidney fibrotic lesion area to total kidney area ratio left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney integrity trait male 238.0 days-252.0 days 15 0.48 % 0.11 0.43 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days 100384 2460
WKY artery tunica media width to artery inner diameter ratio left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney blood vessel morphology trait male 238.0 days-252.0 days 15 1.82 null 0.15 0.58 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days 100388 2460
WKY artery tunica media width to artery inner diameter ratio left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney blood vessel morphology trait male 238.0 days-252.0 days 15 1.56 null 0.1 0.39 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days 100387 2460
WKY plasma sodium level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood sodium amount male 112.0 days 7 148.97 mmol/l 4.08 10.79 inductively coupled plasma-atomic emission spectrometry 0.0 99090 2218
WKY kidney renin level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. kidney renin amount male 112.0 days 5 136.5 ng/ml/h 14.1 31.53 enzyme or transport activity assay 0.0 99099 2218
WKY kidney renin level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. kidney renin amount male 112.0 days 6 145.3 ng/ml/h 11.1 27.19 enzyme or transport activity assay 0.0 99100 2218
WKY body weight streptozotocin (60 mg/kg) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 259.65 g 18.96 59.96 body weighing method 0.0 99108 2219
WKY body weight streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 295.56 g 21.89 69.22 body weighing method 0.0 99110 2219
WKY body weight streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 286.6 g 21.95 69.41 body weighing method 0.0 99112 2219
WKY single kidney wet weight to body weight ratio streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 4.73 g/kg 0.37 1.17 post excision weight measurement 0.0 99117 2219
WKY timed urine volume streptozotocin (60 mg/kg) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 140.19 ml/d 10.38 32.82 urine volume measurement method 0.0 99120 2219
WKY timed urine volume streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 62.68 ml/d 15.67 49.55 urine volume measurement method 0.0 99122 2219
WKY plasma very low density lipoprotein cholesterol level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood VLDL cholesterol amount male  days 7 8.11 mg/dl 0.77 2.04 enzymatic cholesterol assay 0.0 98907 2178
WKY plasma low density lipoprotein cholesterol level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood LDL cholesterol amount male  days 7 7.72 mg/dl 0.77 2.04 enzymatic cholesterol assay 0.0 98911 2178
WKY plasma high density lipoprotein cholesterol level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood HDL cholesterol amount male  days 7 28.57 mg/dl 1.16 3.06 enzymatic cholesterol assay 0.0 98914 2178
WKY plasma triglyceride level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood triglyceride amount male  days 7 0.67 mmol/l 0.04 0.11 enzymatic triglyceride assay 0.0 98919 2178
WKY blood very low density lipoprotein triglyceride level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood VLDL triglyceride amount male  days 7 0.96 mg/dl 0.2 0.53 enzymatic triglyceride assay 0.0 98922 2178
WKY plasma renin activity level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 12 7.4 ng/ml/h 0.8 2.77 radioimmunoassay 0.0 PA IV 50mg/kg 100425 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 12 206.8 ng/ml/h 20.7 71.71 radioimmunoassay 0.0 PA IV 50mg/kg 100426 2479
WKY body weight 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 8 317.0 g 10.0 28.28 body weighing method 0.0 100430 2479
WKY hematocrit 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 9 41.0 % 1.0 3.0 hematocrit analysis 0.0 100436 2479
WKY systolic blood pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 9 106.0 mmHg 3.0 9.0 tail cuff plethysmography 0.0 100445 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 9 42.0 % 1.0 3.0 hematocrit analysis 0.0 PA IV 50mg/kg 490 days 100444 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 7 112.0 mmHg 5.0 13.23 tail cuff plethysmography 0.0 PA IV 50mg/kg 15 days 100446 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 8 113.0 mmHg 4.0 11.31 tail cuff plethysmography 0.0 PA IV 50mg/kg 490 days 100452 2479
WKY glomerular filtration rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 1.17 ml/min 0.05 0.15 inulin analysis by liquid phase colorimetry 0.0 100454 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.38 ml/min 0.08 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100456 2479
WKY glomerular filtration rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 1.51 ml/min 0.12 0.36 inulin analysis by liquid phase colorimetry 0.0 100460 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 10 1.4 g/dl 0.1 0.32 radial immunodiffusion assay 0.0 PA IV 50mg/kg 23 days 100417 2479
WKY serum albumin level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 11 3.7 g/dl 0.2 0.66 radial immunodiffusion assay 0.0 100418 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 10 100.3 ng/ml/h 18.6 58.82 radioimmunoassay 0.0 PA IV 50mg/kg 23 days 100423 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 50.0 nl/min 3.0 9.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg sngfr 100520 2479
WKY single nephron filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.28 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 snff 100524 2479
WKY afferent arteriolar plasma flow rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 165.0 nl/min 17.0 51.0 inulin analysis by liquid phase colorimetry 0.0 afferent arteriolar plasma flow rate 100527 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 18.0 x 10E10 dyne x s/cm5 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 pe 100542 2479
WKY mean proximal tubular hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 16.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pt 100541 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 24.0 x 10E10 dyne x s/cm5 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pe 100546 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 35.0 mmHg 3.0 7.35 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days dp 100548 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 1.49 x 10E10 dyne x s/cm5 0.11 0.33 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg ra 100555 2479
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 8 350.0 mg/dl 18.0 50.91 machine read blood glucose test strip 0.0 unx 28 days 99941 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.52 ml/min/100g 0.03 0.07 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99947 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 7 2.16 ml/min/100g 0.18 0.48 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99950 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 8 2.33 ml/min/100g 0.09 0.25 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99952 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 7 10.0 mmHg/ml/min 0.6 1.59 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99960 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 8 9.2 mmHg/ml/min 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99963 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 8 38.02 ml/d 5.33 15.07 metabolic cage urine volume measurement method 0.0 unx 28 days 99967 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 6 44.93 ml/d 8.78 21.52 metabolic cage urine volume measurement method 0.0 unx 28 days 99969 2378
WKY heart left ventricle fractional shortening sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 5 51.5 % 1.7 3.8 echocardiography 0.0 lad occlusion sham 210 days 100303 2460
WKY heart left ventricle end-diastolic diameter sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 5 7.9 mm 0.2 0.45 echocardiography 0.0 lad occlusion sham 210 days 100306 2460
WKY heart left ventricle end-diastolic diameter left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 32 10.6 mm 0.3 1.7 echocardiography 0.0 lad occlusion 210 days 100308 2460
WKY heart rate sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart pumping trait male 266.0 days-280.0 days 5 398.0 beats/min 37.0 82.73 echocardiography 0.0 lad occlusion sham 210 days 100312 2460
WKY heart rate left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart pumping trait male 266.0 days-280.0 days 32 373.0 beats/min 15.0 84.85 echocardiography 0.0 lad occlusion 210 days 100314 2460
WKY left ventricular end-systolic blood pressure sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 5 10 min mean continuous mean 93.0 mmHg 5.8 12.97 vascular transducer tipped catheter 0.0 lad occlusion sham 210 days 100321 2460
WKY diastolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 32 10 min mean continuous mean 47.6 mmHg 2.7 15.27 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100320 2460
WKY diastolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 16 10 min mean continuous mean 53.0 mmHg 5.2 20.8 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100319 2460
WKY left ventricular end-diastolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 32 10 min mean continuous mean 5.96 mmHg 0.84 4.75 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100326 2460
WKY heart left ventricle end-diastolic diameter sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 12 8.3 mm 0.2 0.69 echocardiography 0.0 lad occlusion sham 196 days 100339 2460
WKY heart left ventricle fractional shortening left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 30 15.8 % 0.7 3.83 echocardiography 0.0 lad occlusion 196 days 100350 2460
WKY heart left ventricle fractional shortening left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 20 15.1 % 1.0 4.47 echocardiography 0.0 lad occlusion 196 days 100349 2460
WKY E/A wave ratio sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood flow trait male 238.0 days-252.0 days 12 1.39 null 0.15 0.52 echocardiography 0.0 lad occlusion sham 196 days e/a wave 100354 2460
WKY right kidney wet weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 12 1.38 g 0.07 0.24 post excision weight measurement 0.0 lad occlusion sham 196 days 100357 2460
WKY right kidney wet weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 15 1.35 g 0.04 0.17 post excision weight measurement 0.0 lad occlusion 196 days 100359 2460
WKY timed urine volume sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 13.9 ml/d 1.6 4.23 urine volume measurement method 0.0 lad occlusion sham 196 days 100360 2460
WKY plasma creatinine level sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.41 mg/dl 0.03 0.07 plasma creatinine analysis 0.0 lad occlusion sham 196 days 100363 2460
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 1.13 x 10E10 dyne x s/cm5 0.12 0.36 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 re 100557 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 6 0.84 x 10E10 dyne x s/cm5 0.1 0.24 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days re 100558 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 4.5 ml/min 0.21 0.63 p-aminohippurate analysis by liquid phase colorimetry 0.0 100463 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 7 3.66 ml/min 0.62 1.64 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100464 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 9 148.0 mmol/l 1.0 3.0 automated plasma analysis 0.0 PA IV 50mg/kg 100485 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 8 142.0 mmol/l 5.0 14.14 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100488 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 5 5.8 mmol/l 0.4 0.89 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100492 2479
WKY urine sodium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 8 0.63 mEq/d 0.03 0.08 urine sodium analysis 0.0 100502 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 8 0.3 mEq/d 0.04 0.12 urine sodium analysis 0.0 PA IV 50mg/kg 100504 2479
WKY urine potassium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 9 0.52 mEq/d 0.1 0.3 urine potassium analysis 0.0 100508 2479
WKY urine potassium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 8 0.85 mEq/d 0.04 0.12 urine potassium analysis 0.0 100511 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 8 1.71 mEq/d 0.35 0.98 urine potassium analysis 0.0 PA IV 50mg/kg 490 days 100515 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 9 2.16 mEq/d 0.27 0.82 urine potassium analysis 0.0 PA IV 50mg/kg 490 days 100516 2479
WKY urine total protein excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 11 112.0 mg/d 17.0 56.38 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 15 days 100398 2479
WKY urine total protein excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 10 5.0 mg/d 1.0 3.16 metabolic cage urine volume measurement method 0.0 100397 2479
WKY serum total cholesterol level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 10 65.0 mg/dl 5.0 15.81 serum total cholesterol measurement test 0.0 100403 2479
WKY serum total cholesterol level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 11 73.0 mg/dl 7.0 23.22 serum total cholesterol measurement test 0.0 100406 2479
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 10.9 gx10 0.43 1.13 Randall-Selitto test 108349 3101
WKY measurement of minimal mechanical stimulus needed to elicit evasive reaction control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. tactile sensory behavior trait male 90.0 days-120.0 days 7 11.0 gx10 0.45 1.2 Randall-Selitto test 108353 3101
WKY systolic blood pressure control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 125.3 mmHg 0.68 1.8 tail cuff plethysmography 108357 3101
WKY body weight unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 17 274.0 g 6.0 24.74 body weighing method 0.0 unx 150 days 107447 2378
WKY kidney glomerular surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 17 19.3 x 10E3 um2 4.8 19.79 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107461 2378
WKY heart weight to body weight ratio unilateral nephrectomy (for 150 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass male  days 11 2.4 g/kg 0.1 0.33 post excision weight measurement 0.0 unx 150 days 107450 2378
WKY heart weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass male  days 17 3.2 g/kg 0.1 0.41 post excision weight measurement 0.0 unx 150 days 107452 2378
WKY kidney glomerular surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 16 16.4 x 10E3 um2 4.1 16.4 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107464 2378
WKY kidney glomerular tuft surface area unilateral nephrectomy (for 150 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 11 8.7 x 10E3 um2 2.6 8.62 ex vivo light microscopy with histochemistry 0.0 unx 150 days 107510 2378
WKY kidney glomerular tuft surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 17 13.2 x 10E3 um2 3.3 13.61 ex vivo light microscopy with histochemistry 0.0 unx 150 days 107511 2378
WKY left kidney wet weight to body weight ratio unilateral nephrectomy (for 150 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass male  days 11 3.9 mg/g 0.1 0.33 post excision weight measurement 0.0 unx 150 days 107455 2378
WKY efferent arteriolar hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 18.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 pt 109965 2479
WKY urine total protein excretion rate control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. total urine protein amount male 280.0 days 4 17.0 mg/d 1.5 3.0 urine total protein analysis 0.0 109537 3147
WKY serum creatinine level control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. blood creatinine amount male 350.0 days 4 0.34 mg/dl 0.02 0.04 serum creatinine analysis 0.0 109547 3147
WKY mean arterial blood pressure control condition Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46 arterial blood pressure trait male 112.0 days 28 continuous mean 120.6 mmHg 1.34 7.1 tail cuff plethysmography 0 animals were prewarmed to 34 degrees C for 20 min before BP 65080 206
WKY heart wet weight controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. heart mass female 360.0 days 4 0.55 g 0.02 0.04 post excision weight measurement 0 12594 268
WKY urine calcium excretion rate controlled calcium content diet (0.6 %) (between 4 and 10 days) Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50. urine calcium amount female 60.0 days-66.0 days 3 2.91 mg/d 0.1 0.18 urine analysis 86400.0 67502 753
WKY urine calcium excretion rate controlled calcium content diet (0.6 %) (between 4 and 10 days) Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50. urine calcium amount male 60.0 days-66.0 days 3 0.95 mg/d 0.08 0.13 urine analysis 86400.0 67503 753
WKY urine calcium excretion rate controlled calcium content diet (1.2 %) (between 5 and 9 days) Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12. urine calcium amount male 61.0 days 8 0.78 mg/d 0.07 0.19 spectrophotometry 0.0 67890 831
WKY urine calcium excretion rate controlled calcium content diet (1.2 %) (between 5 and 9 days) Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12. urine calcium amount female 61.0 days 8 2.11 mg/d 0.18 0.5 spectrophotometry 0.0 67892 831
WKY ethanol intake volume to total fluid intake volume ratio controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. drinking behavior trait female 80.0 days-90.0 days 11 45.7 % 3.29 10.9 ex vivo volume measurement method 0.0 69901 1238
WKY serum triglyceride level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 11 231.0 mg/dl 25.0 82.92 serum triglyceride analysis 0.0 PA IV 50mg/kg 19 days 100410 2479
WKY efferent arteriolar plasma protein concentration 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 7.8 g/dl 0.2 0.57 plasma total protein analysis renal efferent arteriole 0.0 ce 100574 2479
WKY glomerular capillary ultrafiltration coefficient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.09 nl/(s x mmHg) 0.01 0.03 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 kf 100589 2479
WKY plasma aldosterone level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood aldosterone amount male 112.0 days 5 470.0 pg/ml 8.0 17.89 radioimmunoassay 0.0 101691 2218
WKY body weight sham surgical control condition Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 42.0 days-56.0 days 12 223.0 g 1.4 4.85 body weighing method 0.0 lad occlusion days 100267 2460
WKY body weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 266.0 days-280.0 days 16 599.0 g 35.0 140.0 body weighing method 0.0 lad occlusion 210 days 100274 2460
WKY body weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 266.0 days-280.0 days 32 574.0 g 38.0 214.96 body weighing method 0.0 lad occlusion 210 days 100275 2460
WKY heart weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 238.0 days-252.0 days 20 1.56 g 0.42 1.86 post excision weight measurement 0.0 lad occlusion 196 days 100277 2460
WKY heart weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 16 1.88 g 0.61 2.42 post excision weight measurement 0.0 lad occlusion 210 days 100280 2460
WKY tibia length left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. tibia length male 266.0 days-280.0 days 32 4.3 cm 0.09 0.51 post excision length measurement 0.0 lad occlusion 210 days 100287 2460
WKY heart left ventricle weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 238.0 days-252.0 days 20 0.96 g 0.12 0.53 post excision weight measurement 0.0 lad occlusion 196 days 100289 2460
WKY lung wet weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. lung mass male 238.0 days-252.0 days 12 1.78 g 0.05 0.16 post excision weight measurement 0.0 lad occlusion sham 196 days 100297 2460
WKY ejection fraction sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 266.0 days-280.0 days 5 86.8 % 1.5 3.35 echocardiography 0.0 lad occlusion sham 210 days 100300 2460
WKY plasma corticosterone level controlled calorie content diet (100 % of calories) (for 14 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood corticosterone amount female  days 6 123.0 ng/ml 32.0 78.38 radioimmunoassay 0.0 99072 2218
WKY body weight controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. body mass male 112.0 days 17 454.0 g 8.0 32.98 body weighing method 0.0 99075 2218
WKY body weight in utero condition (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. body mass male 112.0 days 18 436.0 g 11.0 46.67 body weighing method 0.0 99076 2218
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 1.19 ml/min 0.08 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100599 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 82.0 nl/min 10.0 22.36 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg sngfr 100609 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 67.0 nl/min 13.0 29.07 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg sngfr 100608 2479
WKY systolic blood pressure control condition (for 0 hours) Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. arterial blood pressure trait male 84.0 days 5 125.0 mmHg 2.0 4.47 tail cuff plethysmography 0.0 103470 2826
WKY body weight control condition (for 0 hours) Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1. body mass male 84.0 days 5 260.0 g 7.0 15.65 body weighing method 0.0 103476 2826
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 17 324.0 mg/dl 13.0 53.6 machine read blood glucose test strip 0.0 unx 168 days 99971 2378
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 17 312.0 mg/dl 24.0 98.95 machine read blood glucose test strip 0.0 unx 168 days 99972 2378
WKY hematocrit unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity male  days 11 45.2 % 1.4 4.64 hematocrit analysis 0.0 unx 168 days 99975 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 16 0.66 ml/min/100g 0.02 0.09 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99983 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 17 0.21 null 0.01 0.05 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99987 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 16 0.21 null 0.01 0.03 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99989 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 16 0.67 ml/min/100g 0.02 0.08 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99984 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 17 0.29 null 0.01 0.05 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99986 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 17 3.3 ml/min/100g 0.11 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99992 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 16 3.19 ml/min/100g 0.13 0.52 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99994 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 17 6.6 mmHg/ml/min 0.3 1.24 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99997 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 17 39.46 ml/d 4.61 19.0 metabolic cage urine volume measurement method 0.0 unx 168 days 100001 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 16 6.8 mmHg/ml/min 0.3 1.2 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99999 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 16 49.25 ml/d 5.18 20.74 metabolic cage urine volume measurement method 0.0 unx 168 days 100004 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 16 45.5 ml/d 5.04 20.16 metabolic cage urine volume measurement method 0.0 unx 168 days 100003 2378
WKY timed urine volume sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 13.9 ml/d 1.6 4.23 urine volume measurement method 0.0 lad occlusion sham 196 days 100374 2460
WKY plasma creatinine level left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.47 mg/dl 0.03 0.07 plasma creatinine analysis 0.0 lad occlusion 196 days 100378 2460
WKY plasma creatinine level left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.52 mg/dl 0.04 0.1 plasma creatinine analysis 0.0 lad occlusion 196 days 100379 2460
WKY heart angiotensin I converting enzyme activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 0.08 nmol/min/mg 0.01 0.02 high-performance liquid chromatography 0.0 99086 2218
WKY lung angiotensin I converting enzyme activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 13.33 nmol/min/mg 0.29 0.71 high-performance liquid chromatography 0.0 99087 2218
WKY plasma potassium level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood potassium amount male 112.0 days 7 10.28 mmol/l 0.41 1.08 inductively coupled plasma-atomic emission spectrometry 0.0 99091 2218
WKY plasma potassium level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. blood potassium amount male 112.0 days 7 11.98 mmol/l 1.12 2.96 inductively coupled plasma-atomic emission spectrometry 0.0 99092 2218
WKY urine sodium level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. urine sodium amount male 112.0 days 7 57.21 mmol/l 17.0 44.98 inductively coupled plasma-atomic emission spectrometry 0.0 99093 2218
WKY blood glucose level streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 523.26 mg/dl 27.18 85.95 radioimmunoassay 0.0 99104 2219
WKY single kidney wet weight to body weight ratio streptozotocin (60 mg/kg) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 5.47 g/kg 0.46 1.45 post excision weight measurement 0.0 99114 2219
WKY body weight streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. body mass male 156.0 days 10 261.43 g 21.34 67.48 body weighing method 0.0 99109 2219
WKY timed urine volume vehicle control condition (1 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. urine output male 156.0 days 10 17.1 ml/d 1.57 4.96 urine volume measurement method 0.0 99119 2219
WKY plasma very low density lipoprotein cholesterol level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood VLDL cholesterol amount male  days 7 2.7 mg/dl 0.39 1.02 enzymatic cholesterol assay 0.0 98906 2178
WKY plasma high density lipoprotein cholesterol level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood HDL cholesterol amount male  days 7 21.62 mg/dl 1.54 4.09 enzymatic cholesterol assay 0.0 98915 2178
WKY blood very low density lipoprotein triglyceride level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. blood VLDL triglyceride amount male  days 7 1.76 mg/dl 0.16 0.42 enzymatic triglyceride assay 0.0 98923 2178
WKY kidney angiotensin I converting enzyme 2 activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 1.69 nmol/min/mg 0.28 0.63 high-performance liquid chromatography 0.0 99079 2218
WKY lung angiotensin I converting enzyme 2 activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 0.14 nmol/min/mg 0.02 0.05 high-performance liquid chromatography 0.0 99081 2218
WKY heart angiotensin I converting enzyme activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 0.08 nmol/min/mg 0.01 0.02 high-performance liquid chromatography 0.0 99083 2218
WKY body weight 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 9 244.0 g 8.0 24.0 body weighing method 0.0 100427 2479
WKY hematocrit 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 9 44.0 % 1.0 3.0 hematocrit analysis 0.0 100442 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 8 44.0 % 1.0 2.83 hematocrit analysis 0.0 PA IV 50mg/kg 490 days 100443 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 9 121.0 mmHg 2.0 6.0 tail cuff plethysmography 0.0 PA IV 50mg/kg 100449 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 7 0.31 ml/min 0.05 0.13 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100455 2479
WKY glomerular filtration rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 1.34 ml/min 0.06 0.17 inulin analysis by liquid phase colorimetry 0.0 100457 2479
WKY serum albumin level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 10 3.5 g/dl 0.2 0.63 radial immunodiffusion assay 0.0 100415 2479
WKY plasma renin activity level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 11 8.8 ng/ml/h 1.0 3.32 radioimmunoassay 0.0 PA IV 50mg/kg 23 days 100422 2479
WKY afferent arteriolar plasma flow rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 191.0 nl/min 16.0 45.25 inulin analysis by liquid phase colorimetry 0.0 afferent arteriolar plasma flow rate 100529 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 6 50.0 mmHg 3.0 7.35 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pgc 100533 2479
WKY glomerular capillary hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 46.0 mmHg 2.0 5.66 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pgc 100536 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 22.0 x 10E10 dyne x s/cm5 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pe 100545 2479
WKY body weight unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 7 268.0 g 13.0 34.39 body weighing method 0.0 unx 28 days 99935 2378
WKY body weight unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 8 233.0 g 5.0 14.14 body weighing method 0.0 unx 28 days 99938 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 8 8.8 mmHg/ml/min 0.5 1.41 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99962 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 8 23.47 ml/d 1.73 4.89 metabolic cage urine volume measurement method 0.0 unx 28 days 99966 2378
WKY heart left ventricle end-diastolic diameter left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 266.0 days-280.0 days 16 10.8 mm 0.3 1.2 echocardiography 0.0 lad occlusion 210 days 100307 2460
WKY left ventricular end-systolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 16 10 min mean continuous mean 73.5 mmHg 4.7 18.8 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100322 2460
WKY left ventricular end-diastolic blood pressure sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 5 10 min mean continuous mean 5.5 mmHg 2.4 5.37 vascular transducer tipped catheter 0.0 lad occlusion sham 210 days 100324 2460
WKY left ventricular end-systolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 32 10 min mean continuous mean 67.5 mmHg 3.9 22.06 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100323 2460
WKY serum potassium level left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood potassium amount male 266.0 days-280.0 days 16 5.0 mmol/l 0.19 0.76 automated serum potassium test 0.0 lad occlusion 210 days 100334 2460
WKY serum sodium level left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood sodium amount male 266.0 days-280.0 days 16 153.5 mmol/l 2.1 8.4 automated serum sodium test 0.0 lad occlusion 210 days 100331 2460
WKY heart left ventricle end-diastolic diameter left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 20 10.6 mm 0.2 0.89 echocardiography 0.0 lad occlusion 196 days 100340 2460
WKY heart posterior wall thickness sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle posterior wall thickness male 238.0 days-252.0 days 12 0.17 cm 0.01 0.03 echocardiography 0.0 lad occlusion sham 196 days 100345 2460
WKY heart left ventricle fractional shortening sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-diastolic diameter male 238.0 days-252.0 days 12 41.1 % 3.0 10.39 echocardiography 0.0 lad occlusion sham 196 days 100348 2460
WKY timed urine volume left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 10.6 ml/d 2.2 5.82 urine volume measurement method 0.0 lad occlusion 196 days 100362 2460
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 3.03 x 10E10 dyne x s/cm5 0.22 0.66 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg rt 100565 2479
WKY total arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 1.53 x 10E10 dyne x s/cm5 0.12 0.34 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg rt 100566 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 3.79 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100467 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 9 4.99 ml/min 0.5 1.5 p-aminohippurate analysis by liquid phase colorimetry 0.0 100469 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 100472 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 7 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100473 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 8 4.7 mmol/l 0.3 0.85 automated plasma analysis 0.0 PA IV 50mg/kg 100495 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 7 0.03 mEq/d 0.01 0.02 urine sodium analysis 0.0 PA IV 50mg/kg 15 days 100500 2479
WKY urine potassium excretion rate 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 9 1.93 mEq/d 0.27 0.82 urine potassium analysis 0.0 100514 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 10 115.0 mg/d 10.0 31.62 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 15 days 100399 2479
WKY systolic blood pressure control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 123.4 mmHg 0.76 2.0 tail cuff plethysmography 108365 3101
WKY systolic blood pressure diclofenac (40 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 122.9 mmHg 0.79 2.1 tail cuff plethysmography 60 min 0.1% methylcellulose per os 108367 3101
WKY body weight unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 16 267.0 g 9.0 36.0 body weighing method 0.0 unx 150 days 107449 2378
WKY body weight unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. body mass male  days 16 261.0 g 7.0 28.0 body weighing method 0.0 unx 150 days 107448 2378
WKY kidney glomerular tuft surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 16 11.7 x 10E3 um2 2.9 11.6 ex vivo light microscopy with histochemistry 0.0 unx 150 days 107514 2378
WKY heart weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass male  days 16 3.1 g/kg 0.1 0.4 post excision weight measurement 0.0 unx 150 days 107454 2378
WKY systolic blood pressure control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. arterial blood pressure trait male 350.0 days 4 124.0 mmHg 3.5 7.0 tail cuff plethysmography 0.0 109529 3147
WKY heart weight to body weight ratio controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. heart mass male 360.0 days 4 2.5 g/kg 0.1 0.2 post excision weight measurement 0 12593 268
WKY systolic blood pressure controlled sodium content diet (0.4 %) (for 63 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. arterial blood pressure trait female 91.0 days 4 serial mean 127.0 mmHg 5.75 11.5 tail cuff photoplethysmography 0 UR1000; Ueda average of 3 consistent readings 12585 268
WKY body weight controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days) Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81. body mass male 360.0 days 4 318.0 g 6.65 13.3 body weighing method 0 12588 268
WKY ethanol intake volume to total fluid intake volume ratio controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days) Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54. drinking behavior trait male 80.0 days-90.0 days 5 10.2 % 1.65 3.7 ex vivo volume measurement method 0.0 69900 1238
WKY body weight 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 11 319.0 g 5.0 16.58 body weighing method 0.0 100394 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 12 312.0 g 4.0 13.86 body weighing method 0.0 PA IV 50mg/kg 100396 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 12 104.0 mg/dl 10.0 34.64 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 100408 2479
WKY serum triglyceride level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male  days 10 61.0 mg/dl 5.0 15.81 serum triglyceride analysis 0.0 100409 2479
WKY afferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 8 5.5 g/dl 0.1 0.28 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg ca 100571 2479
WKY efferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male  days 6 5.0 g/dl 0.1 0.24 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg 23 days ce 100573 2479
WKY afferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 18.1 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 pia 100577 2479
WKY afferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 18.0 mmHg 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 pia 100579 2479
WKY afferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 18.0 mmHg 0.3 0.85 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg pia 100581 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 33.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg pie 100585 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 5 119.0 mmHg 3.0 6.71 tail cuff plethysmography 0.0 PA IV 50mg/kg 100592 2479
WKY systolic blood pressure controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. arterial blood pressure trait male 112.0 days 5 undefined 104.0 mmHg 2.0 4.47 tail cuff plethysmography 0.0 101683 2218
WKY mean arterial blood pressure controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. arterial blood pressure trait male 112.0 days 6 undefined 79.0 mmHg 2.0 4.9 tail cuff plethysmography 0.0 101686 2218
WKY right kidney wet weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 12 1.38 g 0.07 0.24 post excision weight measurement 0.0 lad occlusion sham 196 days 100371 2460
WKY heart left ventricle infarction size to total heart left ventricle size ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle integrity trait male 266.0 days-280.0 days 16 31.8 % 10.1 40.4 ex vivo microscopy with digital image analysis 0.0 lad occlusion 210 days 100265 2460
WKY body weight left anterior descending coronary artery occlusion then vehicle control condition Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 42.0 days-56.0 days 30 225.0 g 1.8 9.86 body weighing method 0.0 lad occlusion days 100269 2460
WKY body weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. body mass male 238.0 days-252.0 days 12 566.0 g 17.0 58.89 body weighing method 0.0 lad occlusion sham 196 days 100270 2460
WKY heart weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 238.0 days-252.0 days 30 1.57 g 0.28 1.53 post excision weight measurement 0.0 lad occlusion 196 days 100278 2460
WKY heart weight sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 5 1.27 g 0.07 0.16 post excision weight measurement 0.0 lad occlusion sham 210 days 100279 2460
WKY heart weight to tibia length ratio sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 5 0.28 g/cm 0.01 0.02 post excision weight measurement 0.0 lad occlusion sham 210 days 100282 2460
WKY heart weight to tibia length ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart mass male 266.0 days-280.0 days 32 0.31 g/cm 0.04 0.23 post excision weight measurement 0.0 lad occlusion 210 days 100284 2460
WKY heart left ventricle weight sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 238.0 days-252.0 days 12 0.85 g 0.03 0.09 post excision weight measurement 0.0 lad occlusion sham 196 days 100288 2460
WKY heart left ventricle weight left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 238.0 days-252.0 days 30 0.97 g 0.08 0.43 post excision weight measurement 0.0 lad occlusion 196 days 100290 2460
WKY heart left ventricle weight to tibia length ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 16 0.24 g/cm 0.03 0.12 post excision weight measurement 0.0 lad occlusion 210 days lv/tl 100295 2460
WKY heart left ventricle weight left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 32 0.93 g 0.1 0.54 post excision weight measurement 0.0 lad occlusion 210 days 100293 2460
WKY heart left ventricle weight to tibia length ratio left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle mass male 266.0 days-280.0 days 32 0.21 g/cm 0.02 0.11 post excision weight measurement 0.0 lad occlusion 210 days 100296 2460
WKY body weight controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. body mass not specified 1.0 days 26 6.64 g 0.14 0.71 body weighing method 0.0 99073 2218
WKY body weight in utero condition (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. body mass not specified 1.0 days 36 4.91 g 0.15 0.9 body weighing method 0.0 99074 2218
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 1.49 ml/min 0.09 0.2 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100597 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.32 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100604 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.28 null 0.03 0.09 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100607 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 65.0 nl/min 9.0 20.12 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg sngfr 100610 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 5 0.16 nl/(s x mmHg) 0.05 0.1 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg kf 100617 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 5 270.0 nl/min 44.0 98.39 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg qa 100612 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 5 62.0 mmHg 2.0 4.47 micropuncture fluid collection 0.0 PA IV 50mg/kg pgc 100614 2479
WKY blood glucose level unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 11 76.0 mg/dl 1.0 3.32 machine read blood glucose test strip 0.0 unx 168 days 99970 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 17 0.5 ml/min/100g 0.03 0.12 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99981 2378
WKY hematocrit unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. erythrocyte quantity male  days 16 44.5 % 0.6 2.4 hematocrit analysis 0.0 unx 168 days 99979 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 16 0.22 null 0.01 0.04 inulin analysis by liquid phase colorimetry 0.0 unx 168 days 99988 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 17 1.72 ml/min/100g 0.11 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99991 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male  days 16 7.1 mmHg/ml/min 0.3 1.2 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99998 2378
WKY ejection fraction left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 266.0 days-280.0 days 32 40.5 % 2.4 13.58 echocardiography 0.0 lad occlusion 210 days 100302 2460
WKY body weight control condition Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. body mass male 245.0 days 7 373.6 g 11.11 29.4 body weighing method 0.0 99849 2338
WKY heart weight to body weight ratio control condition Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6. heart mass male 245.0 days 7 3.7 g/kg 0.04 0.1 post excision weight measurement 0.0 99853 2338
WKY kidney fibrotic lesion area to total kidney area ratio left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney integrity trait male 238.0 days-252.0 days 15 0.75 % 0.13 0.5 ex vivo light microscopy with histochemistry and digital image analysis 0.0 lad occlusion 196 days 100385 2460
WKY plasma renin activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. renin activity male 112.0 days 5 0.43 ng/ml/h 0.05 0.11 enzyme or transport activity assay 0.0 99097 2218
WKY plasma renin activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. renin activity male 112.0 days 6 0.48 ng/ml/h 0.08 0.2 enzyme or transport activity assay 0.0 99098 2218
WKY blood glucose level streptozotocin (60 mg/kg) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 520.92 mg/dl 28.8 91.07 radioimmunoassay 0.0 99102 2219
WKY blood glucose level streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 533.7 mg/dl 25.56 80.83 radioimmunoassay 0.0 99103 2219
WKY blood glucose level streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. blood glucose amount male 156.0 days 10 534.6 mg/dl 22.5 71.15 radioimmunoassay 0.0 99106 2219
WKY single kidney wet weight to body weight ratio streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14. kidney mass male 156.0 days 10 5.42 g/kg 0.51 1.61 post excision weight measurement 0.0 99115 2219
WKY liver cholesterol level standard diet (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. liver cholesterol amount male  days 7 3.92 mg/g 0.24 0.63 enzymatic cholesterol assay 0.0 98894 2178
WKY liver cholesterol level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. liver cholesterol amount male  days 7 5.89 mg/g 0.34 0.91 enzymatic cholesterol assay 0.0 98895 2178
WKY liver triglyceride level controlled cholesterol content diet (1 %) (for 20 days) Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25. liver triglyceride amount male  days 7 19.01 mg/g 1.98 5.24 enzymatic triglyceride assay 0.0 98899 2178
WKY lung angiotensin I converting enzyme 2 activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 0.07 nmol/min/mg 0.02 0.04 high-performance liquid chromatography 0.0 99078 2218
WKY kidney angiotensin I converting enzyme 2 activity level controlled in utero environment (30 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 6 1.56 nmol/min/mg 0.37 0.91 high-performance liquid chromatography 0.0 99082 2218
WKY lung angiotensin I converting enzyme activity level controlled in utero environment (100 % of calories) (for 22 days) Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3. angiotensin I-converting enzyme activity male 112.0 days 5 9.05 nmol/min/mg 1.46 3.26 high-performance liquid chromatography 0.0 99084 2218
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 10 241.0 g 5.0 15.81 body weighing method 0.0 PA IV 50mg/kg 15 days 100393 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 5 245.0 g 12.0 26.83 body weighing method 0.0 PA IV 50mg/kg 15 days 100429 2479
WKY body weight 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male  days 9 412.0 g 6.0 18.0 body weighing method 0.0 100433 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 9 43.0 % 1.0 3.0 hematocrit analysis 0.0 PA IV 50mg/kg 100440 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male  days 5 35.0 % 1.0 2.24 hematocrit analysis 0.0 PA IV 50mg/kg 23 days 100438 2479
WKY systolic blood pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 8 117.0 mmHg 2.0 5.66 tail cuff plethysmography 0.0 100448 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 8 100.0 mmHg 1.0 2.83 tail cuff plethysmography 0.0 PA IV 50mg/kg 100450 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male  days 9 96.0 mmHg 2.0 6.0 tail cuff plethysmography 0.0 PA IV 50mg/kg 490 days 100453 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 1.28 ml/min 0.06 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100458 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 1.14 ml/min 0.13 0.37 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100461 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male  days 12 3.6 g/dl 0.1 0.35 radial immunodiffusion assay 0.0 PA IV 50mg/kg 100420 2479
WKY plasma renin activity level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male  days 11 11.9 ng/ml/h 1.0 3.32 radioimmunoassay 0.0 100424 2479
WKY single nephron glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 61.0 nl/min 3.0 8.49 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100521 2479
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 6 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days snff 100523 2479
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.31 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg snff 100525 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 6 186.0 nl/min 17.0 41.64 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days afferent arteriolar plasma flow rate 100528 2479
WKY glomerular capillary hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 47.0 mmHg 2.0 5.66 inulin analysis by liquid phase colorimetry 0.0 pgc 100534 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 68.0 mmHg 2.0 6.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pgc 100535 2479
WKY afferent arteriolar plasma flow rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 244.0 nl/min 21.0 59.4 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg afferent arteriolar plasma flow rate 100531 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 19.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pt 100540 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 8 17.0 x 10E10 dyne x s/cm5 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 pe 100544 2479
WKY glomerular transcapillary hydraulic pressure gradient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 35.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 dp 100547 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 9 48.0 mmHg 2.0 6.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg dp 100550 2479
WKY afferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 1.74 x 10E10 dyne x s/cm5 0.18 0.54 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 ra 100552 2479
WKY glomerular transcapillary hydraulic pressure gradient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 31.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg dp 100551 2479
WKY blood glucose level unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. blood glucose amount male  days 6 367.0 mg/dl 12.0 29.39 machine read blood glucose test strip 0.0 unx 28 days 99944 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 8 0.54 ml/min/100g 0.02 0.05 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99948 2378
WKY glomerular filtration rate to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 6 0.5 ml/min/100g 0.02 0.06 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99949 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 8 2.32 ml/min/100g 0.11 0.31 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99953 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 7 0.23 null 0.01 0.03 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99955 2378
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male  days 6 2.42 ml/min/100g 0.09 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99954 2378
WKY renal filtration fraction unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. glomerular filtration trait male  days 6 0.21 null 0.01 0.03 inulin analysis by liquid phase colorimetry 0.0 unx 28 days 99959 2378
WKY timed urine volume unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. urine output male  days 8 41.62 ml/d 9.07 25.66 metabolic cage urine volume measurement method 0.0 unx 28 days 99968 2378
WKY heart left ventricle end-systolic diameter left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 266.0 days-280.0 days 32 8.8 mm 0.3 1.7 echocardiography 0.0 lad occlusion 210 days 100311 2460
WKY systolic blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. arterial blood pressure trait male 266.0 days-280.0 days 32 10 min mean continuous mean 75.1 mmHg 2.4 13.58 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100317 2460
WKY maximum rate of positive change in left ventricular blood pressure left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricular blood pressure trait male 266.0 days-280.0 days 16 10 min mean continuous mean 2912.0 mmHg/s 300.0 1200.0 vascular transducer tipped catheter 0.0 lad occlusion 210 days 100328 2460
WKY serum potassium level sham surgical control condition (for 224 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood potassium amount male 266.0 days-280.0 days 5 5.3 mmol/l 0.37 0.83 automated serum potassium test 0.0 lad occlusion sham 210 days 100333 2460
WKY heart ventricle septal wall thickness sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle wall thickness male 238.0 days-252.0 days 12 0.14 cm 0.01 0.03 echocardiography 0.0 lad occlusion sham 196 days 100336 2460
WKY serum potassium level left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood potassium amount male 266.0 days-280.0 days 32 4.9 mmol/l 0.1 0.57 automated serum potassium test 0.0 lad occlusion 210 days 100335 2460
WKY heart ventricle septal wall thickness left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle wall thickness male 238.0 days-252.0 days 20 0.13 cm 0.03 0.13 echocardiography 0.0 lad occlusion 196 days 100337 2460
WKY heart left ventricle end-systolic diameter sham surgical control condition (for 196 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle end-systolic diameter male 238.0 days-252.0 days 12 4.9 mm 0.3 1.04 echocardiography 0.0 lad occlusion sham 196 days 100342 2460
WKY heart posterior wall thickness left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. heart left ventricle posterior wall thickness male 238.0 days-252.0 days 20 0.17 cm 0.01 0.04 echocardiography 0.0 lad occlusion 196 days 100346 2460
WKY ejection fraction left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. cardiac output trait male 238.0 days-252.0 days 30 37.0 % 1.4 7.67 echocardiography 0.0 lad occlusion 196 days 100353 2460
WKY right kidney wet weight left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. kidney mass male 238.0 days-252.0 days 15 1.37 g 0.04 0.14 post excision weight measurement 0.0 lad occlusion 196 days 100358 2460
WKY timed urine volume left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. urine output male 238.0 days-252.0 days 7 11.4 ml/d 2.4 6.35 urine volume measurement method 0.0 lad occlusion 196 days 100361 2460
WKY plasma creatinine level left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days) Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29. blood creatinine amount male 238.0 days-252.0 days 6 0.47 mg/dl 0.03 0.07 plasma creatinine analysis 0.0 lad occlusion 196 days 100364 2460
WKY total arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male  days 9 2.87 x 10E10 dyne x s/cm5 0.28 0.84 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 rt 100562 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 4.18 ml/min 0.47 1.33 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100470 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male  days 8 4.15 ml/min 0.32 0.91 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100468 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 9 0.34 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 100476 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male  days 8 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 100475 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 8 148.0 mmol/l 2.0 5.66 automated plasma analysis 0.0 PA IV 50mg/kg 100486 2479
WKY plasma sodium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 9 143.0 mmol/l 3.0 9.0 automated plasma analysis 0.0 100487 2479
WKY plasma potassium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 9 4.6 mmol/l 0.2 0.6 automated plasma analysis 0.0 100490 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male  days 9 146.0 mmol/l 3.0 9.0 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100489 2479
WKY plasma potassium level 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 8 4.3 mmol/l 0.1 0.28 automated plasma analysis 0.0 100493 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male  days 9 4.7 mmol/l 0.3 0.9 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100498 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 5 0.04 mEq/d 0.01 0.03 urine sodium analysis 0.0 PA IV 50mg/kg 15 days 100501 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/kg) (for 497 days) then puromycin aminonucleoside (50 mg/l) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male  days 9 0.69 mEq/d 0.24 0.73 urine sodium analysis 0.0 PA IV 50mg/kg 490 days 100507 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male  days 5 0.29 mEq/d 0.09 0.19 urine potassium analysis 0.0 PA IV 50mg/kg 15 days 100510 2479
WKY urine total protein excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male  days 12 13.0 mg/d 1.0 3.46 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 100401 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male  days 10 360.0 mg/dl 45.0 142.3 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 19 days 100405 2479
WKY kidney glomerular tuft surface area unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney glomerulus size trait male  days 16 11.1 x 10E3 um2 2.8 11.2 ex vivo light microscopy with histochemistry 0.0 unx 150 days kidney glomerulus surface area (CMO:0003488) 107513 2378
WKY systolic blood pressure control condition Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 122.8 mmHg 0.6 1.6 tail cuff plethysmography 108361 3101
WKY systolic blood pressure diclofenac (20 mg/kg) (for 1 hours) Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9. arterial blood pressure trait male 90.0 days-120.0 days 7 122.6 mmHg 0.74 1.97 tail cuff plethysmography 60 min 0.1% methylcellulose per os 108363 3101
WKY heart weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass male  days 16 3.1 g/kg 0.1 0.4 post excision weight measurement 0.0 unx 150 days 107453 2378
WKY heart weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. heart mass male  days 17 3.5 g/kg 0.1 0.41 post excision weight measurement 0.0 unx 150 days 107451 2378
WKY left kidney wet weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass male  days 17 8.2 mg/g 0.2 0.82 post excision weight measurement 0.0 unx 150 days 107457 2378
WKY left kidney wet weight to body weight ratio unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney mass male  days 16 8.3 mg/g 0.2 0.8 post excision weight measurement 0.0 unx 150 days 107459 2378
WKY efferent arteriolar hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 17.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 pt 109967 2479
WKY efferent arteriolar hydraulic pressure enalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male  days 8 24.0 mmHg 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg pt 109969 2479
WKY systolic blood pressure control condition Macconi D, etal., J Am Soc Nephrol. 2012 Sep;23(9):1496-505. doi: 10.1681/ASN.2011121144. Epub 2012 Jul 19. arterial blood pressure trait male 280.0 days 4 135.0 mmHg 3.5 7.0 tail cuff plethysmography 0.0 109528 3147